Ideal candidates are psoriasis patients with BMI 30 (or 27 with comorbidity), particularly those with suboptimal biologic response, metabolic syndrome, type 2 diabetes, established CVD, or MASH
Because tirzepatide is a peptide, any lower-cost version is most likely to come as a biosimilar or follow-on product rather than a standard chemical generic, and that pathway demands its own clinical proof of comparable pharmacokinetics, pharmacodynamics, and immunogenicity
A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity The FDA recently approved a new use for Wegovy (semaglutide), the blockbuster anti-obesity drug, to reduce the risk of heart attacks and stroke in people with cardiovascular disease who are overweight or obese
What specific medication and starting dosage will I receive at the $149/month tier
This causes a problem in tablet production due to pronounced adhesion of tablets to punches